{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T23:18:08Z","timestamp":1767914288535,"version":"3.49.0"},"reference-count":49,"publisher":"Frontiers Media SA","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2014.00241","type":"journal-article","created":{"date-parts":[[2014,9,5]],"date-time":"2014-09-05T00:13:03Z","timestamp":1409875983000},"source":"Crossref","is-referenced-by-count":53,"title":["Therapeutic Advancements in Multiple Myeloma"],"prefix":"10.3389","volume":"4","author":[{"given":"Alessandro","family":"Gozzetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Candi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Papini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2014,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"11","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/cncr.26447","article-title":"GIMEMA (Gruppo Italiano Malattie Ematologiche dell\u00e2\u20ac\u2122Adulto) myeloma working party extramedullary intracranial localizations of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients","volume":"118","author":"Gozzetti","year":"2012","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/leu.2013.350","article-title":"New drugs and novel mechanisms of action in multiple myeloma 2013: a report from the International Myeloma Working group (IMWG)","volume":"28","author":"Ocio","year":"2014","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1053\/shem.2000.16443","article-title":"Fluorescence in situ hybridization: uses and limitations","volume":"37","author":"Gozzetti","year":"2000","journal-title":"Semin Hematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1182\/blood-2009-07-204651","article-title":"How I treat multiple myeloma in younger patients","volume":"114","author":"Stewart","year":"2009","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1200\/JCO.2010.32.5878","article-title":"Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies","volume":"29","author":"Moreau","year":"2011","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005\u00e2\u20ac\u201c01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00c3\u00b1ol","year":"2012","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1182\/blood-2010-02-271676","article-title":"Once versus twice weekly bortezomib induction therapy with CyBordD in newly diagnosed multiple myeloma","volume":"115","author":"Reeder","year":"2012","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1182\/blood-2011-11-390658","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"B18","first-page":"333","article-title":"Carfilzomib combined with thalidomide and dexamethasone (CTD) is a highly effective induction and consolidation treatment in newly diagnosed patients with multiple myeloma who are transplant candidates","volume":"120","author":"Sonneveld","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","article-title":"Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma","volume":"28","author":"Ladetto","year":"2010","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.2009.25.6081","article-title":"Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences","volume":"28","author":"Barlogie","year":"2010","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1182\/blood-2012-09-451872","article-title":"A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) with a quality of life assessment: NCIC CTG MY.10 Trial","volume":"121","author":"Stewart","year":"2013","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/nrclinonc.2012.100","article-title":"Lenalidomide maintenance \u00e2\u20ac\u201c perils of a premature denouement","volume":"9","author":"Rajkumar","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrclinonc.2012.100-c1","article-title":"Bocchia lenalidomide maintenance in myeloma","volume":"9","author":"Gozzetti","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1182\/asheducation-2013.1.488","article-title":"How should we treat newly diagnosed multiple myeloma patient?","volume":"2013","author":"Mateos","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B32","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1053\/j.seminoncol.2013.07.003","article-title":"Initial treatment of nontransplant patients with multiple myeloma","volume":"40","author":"Cerrato","year":"2013","journal-title":"Semin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1600-0609.2010.01524.x","article-title":"Addition of thalidomide to oral melphalan\/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group","volume":"86","author":"Beksac","year":"2011","journal-title":"Eur J Haematol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","article-title":"Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials","volume":"118","author":"Fayers","year":"2011","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"deposited":{"date-parts":[[2015,2,18]],"date-time":"2015-02-18T19:44:09Z","timestamp":1424288649000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2014.00241\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,4]]},"references-count":49,"URL":"https:\/\/doi.org\/10.3389\/fonc.2014.00241","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,4]]}}}